Bambusa’s additional candidates, BBT003 and BBT004, are in earlier stages of development. BBT003 is being developed for inflammatory bowel disease, while BBT004 is focused on rheumatology.

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND ...

Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced that it has completed the ...

Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its ...

Created with ♥ by RumbleWhen Trisha Williamson started her company Bambusa Jamaica in 2019 she had every intention of carving out as much of that global bamboo market as she could, and for a ...